Acorda Therapeutics has signed an agreement to acquire Finland-based biopharmaceutical firm Biotie Therapies for approximately $363m.

Based in Turku, Biotie is involved in developing therapeutics for central nervous system disorders.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company has designed product candidates to be used in the treatment of Parkinson’s disease and related dementia, as well as other neurodegenerative disorders and an orphan fibrotic liver disease called primary sclerosing cholangitis.

Acorda Therapeutics president and CEO Dr Ron Cohen said: "Our acquisition of Biotie positions Acorda as a leader in Parkinson’s disease therapeutic development, with three clinical-stage compounds that have the potential to improve the lives of people with Parkinson’s."

"The deal will allow Acorda to receive worldwide rights to tozadenant, an oral adenosine A2a receptor antagonist currently in Phase III development in Parkinson’s disease (PD)."

The deal will allow Acorda to receive worldwide rights to tozadenant, an oral adenosine A2a receptor antagonist currently in Phase III development in Parkinson’s disease (PD).

See Also:

The company will also be provided with global rights to SYN120, an oral, 5-HT6 / 5-HT2A dual receptor antagonist for Parkinson’s-related dementia, which is currently in Phase II trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, Acorda will acquire two other assets, including BTT1023 and Selincro.

BTT1023 is a fully human monoclonal antibody that is in Phase II development for the treatment of primary sclerosing cholangitis (PSC), and Selincro is a European Medicines Agency (EMA)-approved therapy for alcohol consumption reduction, which is marketed by Lundbeck in multiple European countries.

Subject to customary closing conditions, the deal is expected to complete in the second quarter of this year.